# nature portfolio

Corresponding author(s):	Rong Li, HaiYang Wang
Last updated by author(s):	Jun 28, 2024

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

		4.0		•	
<.	12	۱۲۱	ıct	ics	•
. )	ıo		ו כ.ו	110.00	٦

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\boxtimes$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

### Software and code

Policy information about <u>availability of computer code</u>

Data collection

Images of both live cell and Immunostaining were collected by Zeiss LSM980 or LSM710 microscope.

 $\label{thm:concentration} \mbox{ ATP concentration was measured using ThermoFisher Varioskan LUX.}$ 

RNA sequencing was used NovaSeq 6000 system.

Young's modulus was measured using the Optics11 Life Chiaro Nanoindenter  $\,$ 

LC/MS-MS was used Agilent 1290 Infinity II/Agilent 6495A Triple Quadrupole LC/MS system

Data analysis

GraphPad Prism 9.3.1 Excel 2016 Origin 2021b DESeq2 3.16

Fiji ImageJ ver. 1.52p

IMARIS 9.9.1 (Oxford Instruments)

R (4.2.2) CRAN 1.0.12

EnhancedVolcano 3.16

clusterProfiler 3.16

Agilent MassHunter Workstation 10.0.127

Agilent Qualitative Analysis 10.0

Huygens Professional software (Scientific Volume Imaging b.v.)

mixOmics packages ropls packages

pheatmap package
priced right package
tidyverse package
(tidyvelse package

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The RNA-seq dataset generated and analyzed during the current study is available in the Gene Expression Omnibus database under accession number GSE270016. The rest of the data generated or analyzed during this study are all included in the published article and its supplementary information files. Source data are provided with this paper.

Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation),

## Research involving human participants, their data, or biological material

2	<u>and sexual orientation</u> and <u>race, ethnicity and racism</u> .		
	Reporting on sex and gender	N/A	
	Reporting on race, ethnicity, or other socially relevant groupings	N/A	
	Population characteristics	N/A	
	Recruitment	N/A	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Ethics oversight

Please select the one below	$\prime$ that is the best fit for your research.	. If you are not sure,	, read the appropriate sections before maki	ng your selection.
X Life sciences	Behavioural & social sciences	Ecological, ev	olutionary & environmental sciences	

For a reference copy of the document with all sections, see <a href="mailto:nature.com/documents/nr-reporting-summary-flat.pdf">nature.com/documents/nr-reporting-summary-flat.pdf</a>

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

N/A

Sample size

No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications. This has been stated in the Statistics and Reproducibility section of the study.

Data exclusions

All data collected for this study were included and analyzed, and no data were excluded.

Replication

All the experimental finding were reproduced as validated by at least three independent experiments.

No randomization method was used to allocate animals experiments, as these were performed on already randomized animals in each condition.

Blinding Data collection and analysis were not performed blinded to the conditions of the experiments

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & exper	imental systems Methods
n/a Involved in the st	n/a Involved in the study    ChIP-seq     Flow cytometry     MRI-based neuroimaging
Dual use resear	rch of concern
⊠ □ Plants  Antibodies	
Antibodies used	rabbit anti–Ki-67 (#9129S, CST; 1:100), mouse anti-Oct3/4 (sc-5279, Santa Cruz Biotechnology; 1:50) rabbit anti–CDX2 (NB100-2136, Novus Biologicals; 1:100) rabbit anti–RFP (# 600-401-379, Rockland; 1:100) chicken anti–RFP (# 600-901-379, Rockland; 1:100) rabbit anti–Phospho-Histone H2A.X (Ser139) (#9718, CST; 1:100) human anti-Centromere Protein Antibody (ACA, #15-234, Antibodies Incorporated; 1:50) rabbit anti-N Cadherin antibody (ab18203, Abcam; 1:100) rabbit anti-Rec8 antibody (from Lampson Lab; homemade, non-commercial; 1:1000)  For secondary antibodies: Alexa Fluor 488—labeled anti-mouse (Invitrogen, A28181, 1:500) Alexa Fluor 488—labeled anti-rabbit (Invitrogen, A28181, 1:500) Alexa Fluor 568—labeled anti-rabbit (Invitrogen, A28181, 1:500) Alexa Fluor Plus 647—labeled anti-ribodie (Invitrogen, A32933, 1:500) Alexa Fluor Plus 647—labeled anti-mouse (Invitrogen, A28181, 1:500) Alexa Fluor Plus 647—labeled anti-mouse (Invitrogen, A28181, 1:500) Alexa Fluor Plus 647—labeled anti-rabbit (Invitrogen, A28181, 1:500) Alexa Fluor Plus 647—labeled anti-rabbit (Invitrogen, A27040, 1:500) Alexa Fluor Plus 647—labeled anti-rabbit (Invitrogen, A27040, 1:500) Alexa Fluor Plus 647—labeled anti-human (Invitrogen, A48279, 1:500)
Validation	All primary antibodies utilized in this study were validated for compatibility with the species (mouse and human) and intended applications (western blots, immunofluorescence, and immunohistochemistry) either by the manufacturers or through previous publications, as documented in Citeab (https://www.citeab.com).  Clone name / Published Species / Applications / citations anti–Ki-67 (https://www.cellsignal.com/products/primary-antibodies/ki-67-d3b5-rabbit-mab/9129) / Human, Mouse, Rat / IF, Flow / cited 369 times. anti-Oct3/4 (https://www.scbt.com/p/oct-3-4-antibody-c-10) / Human, Mouse, Rat / IHC, IP, WB, IF / cited 2514 times. anti–CDX2 (https://www.novusbio.com/products/cdx2-antibody_nb100-2136) / Human, Mouse/ WB, IP, IF, IHC(P), FCM and ELISA / cited 12 times. anti–RFP (https://www.rockland.com/categories/primary-antibodies/rfp-antibody-pre-adsorbed-600-401-379/) / ELISA, IF, IHC, WB / cited 1187 times. anti–RFP (https://www.rockland.com/categories/primary-antibodies/rfp-antibody-600-901-379/) / ELISA, IF, IHC, WB / cited 62 times. anti–RFP (https://www.rockland.com/categories/primary-antibodies/rfp-antibody-600-901-379/) / ELISA, IF, IHC, WB / cited 62 times. anti–Phospho-Histone H2A.X (Ser139) (https://www.cellsignal.com/products/primary-antibodies/phospho-histone-h2a-x-ser139-20e3-rabbit-mab/9718) / Human, Mouse, Rat / WB, IP, IF, IHC(P), FCM / cited 2237 times. anti-Centromere Protein Antibody (https://www.antibodiesinc.com/products/anti-centromere-protein-antibody-15-234) / Human, Mouse, Rat / WB, IP, IF, IHC, ICC / cited 254 times. anti-N Cadherin antibody (https://www.abcam.com/products/primary-antibodies/n-cadherin-antibody-intercellular-junction-marker-antibody-intercellular-junction-marker-antibody-intercellular-junction-marker-antibody-intercellular-junction-marker-antibody-intercellular-junction-marker-antibody-intercellular-junction-marker-antibody-intercellular-junction-marker-antibody-intercellular-junction-marker-antibody-intercellular-junction-marker-antibody-intercellular-junction-marker-an

## Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

ab18203.html) / Human, Mouse, Rat / WB, IP, IF, IHC, ICC / cited 554 times.

Laboratory animals

ICR mice

MTS-mCherry-GFP1-10 mice (C57BL/6J background)

mTmG mice (FVB background)

B6C3HF2 mice

Unless otherwise noted, all young mice were studied between 2-3 months old and all aged mice were studied at 14-17 months old. Surrogate mothers (B6C3HF2 mice) 3-6 months old.

Rabbit anti-Rec8 antibody (from Lampson Lab) / Mouse / IF, WB/ Used in Chiang et al., Curr Biol. 2010, PubMed 20817534.

The mice were kept under standard conditions, with constant temperature (21-25°C) and humidity (30-70%), and a 12-hour light:12-hour dark cycle with light onset at 07:00.

Wild animals	No wild animals were used in the study.	
Reporting on sex	Follicles and oocytes were obtained from female mice. Sperm for IVF was collected from male mice. Surrogate mothers were female mice.	
Field-collected samples	No field collected samples were used in the study.	
Ethics oversight	The animal experiments conducted in this study were approved by the Institutional Animal Care and Use Committee at the National University of Singapore (protocol R20-0072) and were carried out in compliance with the relevant guidelines and regulations.	

Note that full information on the approval of the study protocol must also be provided in the manuscript.